✦ LIBER ✦

Androgen receptor action in hormone-dependent and recurrent prostate cancer

✍ Scribed by Irina U. Agoulnik; Nancy L. Weigel

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 177 KB
Volume: 99
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.20811

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The importance of androgens and androgen receptors (AR) in primary prostate cancer is well established. Metastatic disease is usually treated with some form of androgen ablation, which is effective for a limited amount of time. The role of AR in prostate cancers that recur despite androgen ablation therapy is less certain. Most of these tumors express prostate specific antigen (PSA), an androgen‐regulated gene; moreover, AR is generally highly expressed in recurrent prostate cancer. We propose that AR continues to play a role in many of these tumors and that it is not only the levels of AR, ligands, and co‐regulators, but also the changes in cell signaling that induce AR action in recurrent prostate cancer. These pathways are, therefore, potential therapeutic targets. J. Cell. Biochem. 99: 362–372, 2006. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Androgen receptor gene mutations in horm

Androgen receptor gene mutations in hormone-refractory prostate cancer

✍ Wall�n, Mika J.; Linja, Marika; Kaartinen, Kaius; Schleutker, Johanna; Visakorpi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Prostate cancer is considered to be one of the most hormone-dependent human malignancies. As a key mediator of hormonal response, the androgen receptor (AR) is believed to have an important role in the progression of prostate cancer. Mutations in the coding region of the AR gene have been found in b

Amplification of the androgen receptor g

Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer

✍ Koivisto, Pasi A.; Rantala, Immo 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 2 views

p53 protein expression of 30 hormone-refractory locally recurrent prostate cancers was compared with their matched untreated primary tumour specimens. In addition, androgen receptor (AR) gene amplification and p53 protein immunostaining were compared. p53 positivity increased during hormonal therapy

Androgen receptor and caveolin-1 in pros

Androgen receptor and caveolin-1 in prostate cancer

✍ Nigel Bennett; John D. Hooper; C. Soon Lee; Glenda C. Gobe 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

## Abstract The androgen receptor (AR) is involved in the development and maintenance of the normal prostate and the development and progression of prostate cancer (PCa). Caveolin‐1 (cav‐1) is an AR co‐regulator. The expression of this integral membrane protein is upregulated in PCa and correlates

Androgen receptor and caveolin-1 in pros

Androgen receptor and caveolin-1 in prostate cancer

✍ Nigel Bennett; John D. Hooper; C. Soon Lee; Glenda C. Gobe 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB

## Abstract Flow diagram of androgen, androgen receptor and caveolin‐1 activity. See Androgen Receptor and Caveolin‐1 in Prostate Cancer by Bennett et al., pp. 961–970.

Molecular regulation of androgen action

Molecular regulation of androgen action in prostate cancer

✍ Scott M. Dehm; Donald J. Tindall 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB

## Abstract Androgens are critical regulators of prostate differentiation and function, as well as prostate cancer growth and survival. Therefore, androgen ablation is the preferred systemic treatment for disseminated prostate cancer. Androgen action is exerted in target tissues via binding the and

Synergistic activation of androgen recep

Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells

✍ Culig, Zoran; Hobisch, Alfred; Hittmair, Anton; Cronauer, Marcus V.; Radmayr, Ch 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

## Background: We investigated modulation of androgen receptor (ar) activity in prostatic tumor cells by luteinizing hormone-releasing hormone (lhrh)-induced increase of the intracellular cyclic adenosine monophosphate (camp) level. ## Methods: Ar transactivation activity was assessed in transien